多發性骨髓瘤藥物市場：按藥物、分佈分類 - 全球預測 2023-2030

預計2023年全球多發性骨髓瘤藥物市場將大幅成長至227億美元，年複合成長率為8.02%，預計2030年將達到驚人的390.2億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球多發性骨髓瘤治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.多發性骨髓瘤治療藥物的全球市場規模與預測為何？

2.在預測期內，COVID-19對全球多發性骨髓瘤治療藥物市場的阻礙因素與影響有哪些？

3.在預測期內，全球多發性骨髓瘤治療藥物市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球多發性骨髓瘤藥物市場的競爭策略是什麼？

5.全球多發性骨髓瘤藥物市場的技術趨勢和法律規範是什麼？

6.全球多發性骨髓瘤治療藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性措施被認為適合進入多發性骨髓瘤藥物全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 多發性骨髓瘤的適應症和盛行率不斷增加
    • 有吸引力的報銷制度支持已開發國家的治療
    • 透過學名藥批准增加藥物供應
  • 抑制因素
    • 嚴格的藥品核准流程
  • 機會
    • 產品開發、藥物臨床臨床實驗和商業化之間的合作
    • 採用標靶治療和皮質類固醇
  • 任務
    • 潛在的副作用
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 多發性骨髓瘤治療藥物市場（依藥物）

• 組蛋白去乙醯化酶抑制劑
• 免疫調節劑
• 單株抗體
• 蛋白酶體抑制劑

第7章 多發性骨髓瘤治療藥物市場分佈

• 醫院藥房
• 線上通路
• 零售藥房

第8章 美洲多發性骨髓瘤藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太地區多發性骨髓瘤藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東及非洲多發性骨髓瘤藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Multiple Myeloma Drug Market is forecasted to grow significantly, with a projected USD 22.70 billion in 2023 at a CAGR of 8.02% and expected to reach a staggering USD 39.02 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Multiple Myeloma Drug Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Multiple Myeloma Drug Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors. The Proteasome Inhibitors is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospital Pharmacy, Online Channel, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Multiple Myeloma Drug Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Multiple Myeloma Drug Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Myeloma Drug Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Myeloma Drug Market?

4. What is the competitive strategic window for opportunities in the Global Multiple Myeloma Drug Market?

5. What are the technology trends and regulatory frameworks in the Global Multiple Myeloma Drug Market?

6. What is the market share of the leading vendors in the Global Multiple Myeloma Drug Market?

7. What modes and strategic moves are considered suitable for entering the Global Multiple Myeloma Drug Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Multiple Myeloma Drug Market, by Drug, 2022 vs 2030
• 4.3. Multiple Myeloma Drug Market, by Distribution, 2022 vs 2030
• 4.4. Multiple Myeloma Drug Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased indication and prevalence of Multiple Myeloma
    • 5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
    • 5.1.1.3. Increased drug availability along with approvals for generics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent drug approval process
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborating product development and drug trials and commercialization
    • 5.1.3.2. Targeted therapy and adoption of Corticosteroids
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Multiple Myeloma Drug Market, by Drug

• 6.1. Introduction
• 6.2. Histone Deacetylase Inhibitors
• 6.3. Immunomodulating Agents
• 6.4. Monoclonal Antibodies
• 6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Channel
• 7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Drug Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2022 VS 2030
• FIGURE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
• FIGURE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
• FIGURE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
• FIGURE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 5. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 10. MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 20. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 21. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 32. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 33. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 34. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 35. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 69. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 70. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 77. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 78. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 79. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 80. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 99. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 100. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 101. MULTIPLE MYELOMA DRUG MARKET LICENSE & PRICING